Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Overview of Precigen Inc (PGEN)
Precigen Inc is a clinical stage biopharmaceutical company that develops and refines innovative gene and cell therapies using cutting-edge synthetic biology and precision technology. With proprietary platforms such as UltraCAR-T and AdenoVerse, the company designs, builds, and regulates complex gene expression programs to address intractable diseases. Its expertise in non-viral gene transfer methods and advanced DNA construction techniques positions the company as a significant innovator across multiple therapeutic areas including immuno-oncology, autoimmune disorders, and infectious diseases.
Core Business and Technological Platforms
Precigen leverages a comprehensive suite of technologies to discover and develop next generation therapeutics. The company utilizes an advanced UltraVector platform for DNA construction, facilitating the design and assembly of gene components. Its UltraCAR-T platform, which employs a non-viral Sleeping Beauty system, enables the rapid manufacturing of personalized cell therapies with an improved safety profile and simplified logistics. Additionally, the AdenoVerse platform uses a library of engineered adenovector serotypes that efficiently deliver gene therapies aimed at modulating immune responses.
Business Model and Collaborations
The business model of Precigen is centered on leveraging its proprietary technology platforms through strategic collaborations with industry experts who bring extensive development, manufacturing, and commercial capabilities. These partnerships generate revenue primarily via technology access fees, milestone payments, royalties, and reimbursement of collaborative costs. This model provides a stable framework for continuous innovation and the effective translation of preclinical discoveries into viable clinical therapies.
Market Position and Competitive Landscape
In the competitive biotechnology arena, Precigen distinguishes itself through its robust research capabilities and a diversified portfolio of therapeutic candidates. Its unique non-viral gene transfer methods and rapid manufacturing techniques set it apart from traditional gene and cell therapy developers. By focusing resources on technologies with high clinical and commercial potential, the company addresses critical unmet needs in the therapeutic landscape, thereby reinforcing its market significance.
Operational Focus and Expertise
Precigen’s operations are built on years of scientific expertise in genetic engineering and computational model integration for therapeutic design. The company’s detailed approach to tailoring gene expression programs allows for improved functional characteristics of immune cells and precise control over therapeutic outcomes. Its methodical approach and dedication to iterative clinical development underscore its commitment to advancing medicine with precision.
Summary of Value Proposition
Precigen excels in translating complex genetic information into transformative therapies with the potential to modify the disease course in challenging therapeutic areas. By continually streamlining its research and operational models, the company ensures that its innovative techniques remain at the forefront of scientific excellence and commercial relevance. The integrated approach of technology, clinical expertise, and strategic partnerships makes Precigen a notable entity within the biopharmaceutical industry.
Precigen, Inc. (Nasdaq: PGEN) announced its fourth quarter and full year 2021 financial results, showcasing a notable 25% increase in total revenues year-over-year. The company reported a net loss of $25 million for Q4, improving from a loss of $39.7 million in the prior year. Key developments include the completion of various clinical trials and a public offering that raised approximately $129.4 million. The company anticipates current cash reserves will fund operations into 2023, supporting its clinical programs focused on gene and cell therapies.
On January 12, 2022, Precigen (PGEN) showcased key updates at the 40th Annual J.P. Morgan Healthcare Conference. Highlights included the completion of enrollment in several Phase 1/1b clinical trials for investigational therapies targeting Acute Myeloid Leukemia (AML), ovarian cancer, and recurrent respiratory papillomatosis (RRP). Notably, the firm reported positive interim data from multiple studies, with plans to initiate multicenter expansions and incorporate repeat dosing regimens. Additionally, Precigen aims for rapid regulatory strategies for its therapies addressing significant unmet medical needs in 2022.
Precigen, a biopharmaceutical company listed on Nasdaq under the ticker PGEN, announced that CEO Helen Sabzevari will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 PM ET. Additionally, she will join a panel discussion on January 11, 2022, at 12:00 PM ET, discussing the cell and gene therapy landscape. Live webcasts of both events can be accessed on Precigen's website.
Precigen presented promising interim results for its PRGN-3006 UltraCAR-T therapy targeting relapsed or refractory acute myeloid leukemia (AML) at the 63rd ASH Annual Meeting. The Phase 1/1b study included 15 patients, showing an overall response rate (ORR) of 50% in the lymphodepletion cohort. Notably, the therapy was well-tolerated, with no dose-limiting toxicities or neurotoxicity. The company anticipates progressing to a multicenter expansion phase to evaluate repeated dosing. These results highlight the potential of UltraCAR-T in transforming AML treatment pathways.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, will have its President and CEO, Helen Sabzevari, participate in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 AM ET. This event can be accessed via the Precigen website. The company is focused on gene and cell therapies aimed at treating urgent diseases, including in the areas of immuno-oncology and autoimmune disorders. More information can be found on their website.
Precigen (Nasdaq: PGEN) announced significant clinical progress during its 2021 R&D Day, showcasing advancements in its UltraCAR-T and AdenoVerse therapy platforms. Highlights include favorable safety and efficacy data from PRGN-3005, PRGN-3006, PRGN-2009, and PRGN-2012 therapies. Notably, PRGN-3006 demonstrated a 50% overall response rate in relapsed or refractory AML patients. Additionally, PRGN-2009 showed promising immune responses in HPV-associated cancers. Future plans include pursuing registrational trials pending dose confirmation. Overall, the event emphasized Precigen's commitment to advancing innovative therapies for complex diseases.
Precigen (Nasdaq: PGEN) will host a virtual event on November 4, 2021, at 11:00 AM ET to discuss updates on its clinical pipeline. The event will present data on several advanced programs, including PRGN-3005 and PRGN-3006 UltraCAR-T, as well as PRGN-2009 and PRGN-2012 AdenoVerse Immunotherapies. Executives and lead investigators from notable institutions will participate. Details for registration and access to the live webcast are available on Precigen's investor relations website.
Precigen has announced that the FDA has cleared its IND application to launch a Phase 1/1b clinical trial for PRGN-3007, targeting advanced ROR1+ hematological and solid tumors. This first-in-class therapy, leveraging Precigen's UltraCAR-T® platform, aims to improve outcomes in patients with cancers like CLL and TNBC by incorporating PD-1 blockade. The trial will assess safety and efficacy in two arms: one for hematological tumors and another for solid tumors. This innovative therapy is expected to mitigate systemic toxicity and reduce treatment costs.
Precigen, Inc. (Nasdaq: PGEN) announced the appointment of Harry Thomasian Jr. as its new chief financial officer (CFO), effective October 18, 2021. With over 35 years of global finance experience, Thomasian will oversee corporate financial strategy, business development, and financing initiatives. Prior to joining Precigen, he held leadership roles at EY, focusing on the life sciences sector. CEO Helen Sabzevari emphasized Thomasian's financial acumen and experience as vital for guiding the company's growth and fiscal strength.
Precigen ActoBio announced encouraging interim data from its Phase 1b/2a clinical study of AG019 ActoBiotics for recent-onset type 1 diabetes. Presenting at the EASD 57th Annual Meeting, results demonstrated AG019’s safety and efficacy, with 100% of adult patients achieving glycated hemoglobin below 7% after monotherapy. The study met primary endpoints; no serious adverse events occurred. AG019 also stabilized C-peptide levels, indicating preserved insulin production. Future investigations will explore AG019's potential as a standalone therapy for type 1 diabetes.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What is the primary focus of Precigen Inc?
How does Precigen generate revenue?
What distinguishes Precigen's technological platforms?
Which therapeutic areas does Precigen target?
How is Precigen positioned in the competitive biotechnology landscape?
What role do partnerships play in Precigen's business model?
